Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

d by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms - aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin FIT data to be acceptable to the FDA for this expanded indication or any other indication, the determinations by regulatory,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... ... 2015 , ... The new Xsample 530 sample changer for vials can be used ... viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) – ... catches the eye about Xsample 530 is its removable magazine, which is easily lifted off ...
(Date:7/28/2015)... ... 28, 2015 , ... In terms of value, aluminium hydroxide ... volume reached close to 1.84 million tonnes in the same year. As of ... the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted a ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... the Deerfield Healthcare Innovations Fund, L.P., which will invest ... therapeutic interventions in genetic diseases, cancer, and orphan diseases. ... that can transform how therapeutics are developed and improve ... The fund, one of the largest healthcare-focused venture funds ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... with explosives in World War II to slow the advance ... use explosives at ski resorts to purposely create avalanches so ... creating the desired effect (a destroyed bridge or avalanche), the ... of matter found within a detonating high explosive. , In ...
... PPD, Inc. (Nasdaq:,PPDI) will release its fiscal year 2008 ... closes. The release will be available on,the PPD Web ... On Wednesday, January 9, 2008, at 9:00 a.m. ... webcast to discuss its financial guidance for,fiscal year 2008. ...
... ... , WHAT: This presentation identifies key challenges facing manufacturers of ... how embedded RFID technology is ... that enhances safety and reliability, increases revenue and brand ...
Cached Biology Technology:Explosives at the microscopic scale produce shocking results 2PPD Announces 2008 Financial Guidance Webcast and Conference Call 2SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... by fungi, bacteria, and algae, is a common component of ... the medical field it,s approved by the FDA as ... surgery as a substance that opens the blood/brain barrier to ... Gazit and Daniel Segal of Tel Aviv University,s Department of ...
... controversial method of mining shale gas, is widespread across Pennsylvania, ... research in the Annals of the New York Academy ... pollution from toxic chemicals, the building of well pads and ... a great deal of controversy, largely because of its impact ...
... 116 million years ago triggered a similar marine ecosystem ... result of global warming, according to research published today ... experts from the universities of Newcastle, UK, Cologne, Frankfurt ... a crash in the marine ecosystem during the mid-Cretaceous ...
Cached Biology News:Artificial sweetener a potential treatment for Parkinson's disease 2Global cooling as significant as global warming 2
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Request Info...
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: